Inventor
RUELLA MARCO
US15 patents
⚠️ This page may combine multiple inventors who share the name “RUELLA MARCO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
10 patentsUS10174095B2Jan 8, 2019
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
NOVARTIS AG41 citations96
US11084880B2Aug 10, 2021
Anti-BCMA chimeric antigen receptor
NOVARTIS AG15 citations93
US10253086B2Apr 9, 2019
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG37 citations93
US11149076B2Oct 19, 2021
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG9 citations84
US11026976B2Jun 8, 2021
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG6 citations82
US12344657B2Jul 1, 2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG1 citations73
US11872249B2Jan 16, 2024
Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
NOVARTIS AG2 citations71
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG1 citations62
USRE49847EFeb 27, 2024
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG0 citations61
UNIV PENNSYLVANIA
4 patentsUS10357514B2Jul 23, 2019
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
UNIV PENNSYLVANIA18 citations82
US11673964B2Jun 13, 2023
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
UNIV PENNSYLVANIA2 citations71
US12227588B2Feb 18, 2025
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
UNIV PENNSYLVANIA0 citations61
US12214037B2Feb 4, 2025
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
UNIV PENNSYLVANIA0 citations61